leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...2223242526272829303132...235236»
  • ||||||||||  tilatamig samrotecan (AZD9592) / AstraZeneca
    Trial completion date, Trial primary completion date, Monotherapy:  EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) -  Mar 2, 2024   
    P1,  N=108, Recruiting, 
    Initiation date: Oct 2023 --> Jun 2024 Trial completion date: Mar 2025 --> Oct 2025 | Trial primary completion date: Mar 2025 --> Oct 2025
  • ||||||||||  misetionamide (GP-2250) / Panavance Therap
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine (clinicaltrials.gov) -  Mar 2, 2024   
    P1,  N=64, Recruiting, 
    Trial completion date: Jun 2029 --> Mar 2030 | Trial primary completion date: Jun 2029 --> Mar 2030 Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
  • ||||||||||  Journal:  SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids. (Pubmed Central) -  Mar 2, 2024   
    In patients with unresectable disease, either FOLFIRINOX, a combination of 5-fluorouracil (5-FU), oxaliplatin and irinotecan, or gemcitabine plus nab-paclitaxel combined with radiation are frontline standard regimens...In conclusion, our study emphasizes the crucial role of CSCs in therapeutic resistance in PC treatment. We recommend using tumor organoids as a model system to explore the impact of CSCs in PC and identify new therapeutic targets.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Review, Journal, BRCA Biomarker, PARP Biomarker:  Next-generation therapies for pancreatic cancer. (Pubmed Central) -  Feb 28, 2024   
    NALIRIFOX (liposomal irinotecan, fluorouracil, leucovorin, oxaliplatin) is an emerging standard of care in the metastatic setting...Olaparib, a poly-ADP-ribose polymerase (PARP) inhibitor, has regulatory approval for maintenance therapy in BRCA-mutated mPDAC along with other targeted agents receiving disease-agnostic approvals including for PDAC with rare fusions and mismatch repair deficiency...There is notable potential for targeted therapies for KRAS-mutated PDAC with opportunity for meaningful benefit for a sizable portion of patients with this disease. Further, emerging approaches are focused on novel immune, tumor microenvironment, and synthetic lethality strategies.
  • ||||||||||  leucovorin calcium / Generic mfg., sulphadiazine / Generic mfg., pyrimethamine / Generic mfg.
    Journal:  Diagnosis of Congenital Toxoplasmosis: Challenges and Management Outcomes. (Pubmed Central) -  Feb 26, 2024   
    During the follow-up, all presented normal psychomotor development without any long-term sequelae. Conclusion The lower incidence in our study, compared to the incidence in Europe, may be related to the decline in the prevalence of toxoplasmosis as well as the effectiveness of measures to prevent primary infection and a well-established program of antenatal screening, followed by the early initiation of treatment during pregnancy to prevent vertical transmission.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial primary completion date, Metastases:  Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy (clinicaltrials.gov) -  Feb 25, 2024   
    P=N/A,  N=51, Recruiting, 
    Moreover, our study also revealed new perspectives on potential biomarkers for clinical efficacy. Trial primary completion date: Jun 2023 --> Aug 2024
  • ||||||||||  Review, Journal, IO biomarker:  Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches. (Pubmed Central) -  Feb 24, 2024   
    Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed...Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy.
  • ||||||||||  fosifloxuridine nafalbenamide (NUC-3373) / NuCana
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  NuTide:323: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer (clinicaltrials.gov) -  Feb 23, 2024   
    P2,  N=171, Recruiting, 
    Such studies may open up an alternative, safe, and well-tolerated treatment for those with the PANS/PANDAS diagnosis. Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Sep 2024
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    P2 data, Journal, Metastases:  Phase II Trial of FOLFIRINOX in Advanced Biliary Tract Cancer. (Pubmed Central) -  Feb 21, 2024   
    The trial suggests that FOLFIRINOX is a potentially effective first-line therapy for unresectable or metastatic BTC with a manageable safety profile. However, the early termination of the study and the introduction of immunotherapy warrant further research to confirm these findings.
  • ||||||||||  Rituxan (rituximab) / Roche
    Enrollment change, Trial completion date, Trial primary completion date:  LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (clinicaltrials.gov) -  Feb 21, 2024   
    P1,  N=64, Recruiting, 
    Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Dec 2023 --> Apr 2024 N=44 --> 64 | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Worsening Cavitary Lung Lesions in a Patient With Metastatic Colorectal Cancer on Stirvaga (Regorafenib) (San Diego Convention Center, Room 6E (Upper Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_8232;    
    Stirvaga, in the absence of other causative factors, likely exhibited a strong anti-angiogenic effect resulting in mass cavitation in our patient with known lung metastases in the setting of stage IV colorectal cancer. These findings were correlated with evolution of a pre-existing lung mass on CT and new cardiopulmonary symptoms not secondary to infection or pulmonary embolism.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., prednisone / Generic mfg.
    Pulmonary Tumor Thrombotic Microangiopathy Leading to the Discovery of Underlying Gastric Adenocarcinoma (San Diego Convention Center, Room 5A-B (Upper Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_7730;    
    Initial imaging was concerning for interstitial lung disease, was started on prednisone taper and developed a new oxygen requirement of 2-4 L. He then developed sudden onset bilateral hip pain with mobility impairment causing him to present to the emergency department...Acute hypoxic respiratory failure in an otherwise healthy male with a cancer diagnosis should raise suspicion for PTTM. Further research is warranted to better understand this lethal condition for earlier diagnosis and timely management.
  • ||||||||||  methotrexate / Generic mfg.
    From Rashes to Ruin: The Methotrexate Misadventure (San Diego Convention Center, Area K (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6018;    
    Case Report: The patient initially presented with a sore throat and neutropenia, and was discharged from the emergency room with a course of Keflex for a urinary tract infection...Leucovorin and urine alkalization were initiated...Addressing these disparities through improved access, health literacy, cultural competence, and communication is crucial to preventing medication-related complications, especially in vulnerable populations. Reducing healthcare disparities can promote equitable access to care and enhance patient safety.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    FOLFOX Induced Interstitial Lung Disease (San Diego Convention Center, Area D (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_3788;    
    Standard of care first-line consists of an infusion of 5-fluorouracil and leucovorin (FL) plus oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)...She was intermittently hypoxic but never required long-term supplemental oxygen therapy and was treated with steroid therapy with a high dose prednisone taper, which vastly improved her symptoms...Here we describe a patient who developed both radiographic and symptomatic evidence of ILD after treatment with FOLFOX with possible preexisting lung disease on imaging. A comprehensive topic review is needed to further understand this association.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Folfox Chemotherapy Induced Lung Fibrosis and Bilateral Pneumothoraxes (San Diego Convention Center, Area D (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_3781;    
    In our case, it is our belief that this patient developed bilateral pneumothoraxes secondary to pulmonary fibrosis, which in turn were likely to have been caused by the patient's oxaliplatin. Our case report represents an uncommon pulmonary side effect of FOLFOX and a unique manifestation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Who's to Blame? A Case of Drug-Induced Pneumonitis With Multiple Potential Culprits (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_1578;    
    He had metastatic sigmoid adenocarcinoma, and had undergone 7 Cycles of Folinic acid, Fluorouracil and Oxaliplatin (FOLFOX) and Cetuximab prior to his admission...(Image 1B) As he was planned for cytoreductive surgery with heated intraperitoneal mitomycin chemotherapy (CRS-HIPEC), he was kept on prednisolone 5mg daily...Discussion This case highlights the difficulties in determining which drug of a combination chemotherapy regime is the culprit. A multi-disciplinary team approach with the oncologist is essential to establish an early diagnosis and treatment of drug-induced pneumonitis.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment. (Pubmed Central) -  Feb 18, 2024   
    FOLFOX regimen, composed of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (OXP), has been used as clinical standard therapeutic regimen in treatments of colorectal cancer (CRC) and esophageal squamous cell carcinoma (ESCC)...Herein, a lipid core-shell nanoparticle codelivery platform was designed for simultaneous encapsulation of variant FOLFOX composed of miriplatin (MiPt), 5-Fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP), calcium folinate (CF) and PD-L1 siRNA (siPD-L1) with high efficiencies, and their synergistic anti-tumor mechanisms were studied, respectively...CF worked as the sensitizer of FdUMP. The enhanced long-term anti-tumor effect of the prepared "all-in-one" formulation compared to free drug regimen and other controls, was verified in heterotopic CRC mice models and ESCC mice models, providing new thoughts for researchers and showing a promising prospect of translation into clinical applications.
  • ||||||||||  oxaliplatin / Generic mfg.
    Trial primary completion date:  METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin (clinicaltrials.gov) -  Feb 15, 2024   
    P2,  N=80, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> Aug 2024 Trial primary completion date: Jun 2023 --> Jun 2024